Tocilizumab May Help in Early Systemic Sclerosis
eMediNexus, 22 February 2021
remove_red_eye 483 Views
#Dermatology #Orthopedics #Pathology and Lab Medicine #Pharmacist #Pulmonary Medicine #Rheumatology
Coronavirus Live Count Map India
remove_red_eye 483 Views
COVID-19 Vaccine Updates
#Dermatology #Orthopedics #Pathology and Lab Medicine #Pharmacist #Pulmonary Medicine #Rheumatology
Treatment with tocilizumab could result in stabilization or improvement in lung function among individuals with early interstitial lung disease associated with systemic sclerosis (SSc-ILD), suggests a new study published in Arthritis & Rheumatology.
This was a post hoc analysis of data from a phase 3, placebo-controlled, double-blind trial of subcutaneous tocilizumab conducted among patients with SSc and progressive skin disease. There were 210 participants in the trial, of which 136 had interstitial lung disease at baseline and received 162 mg tocilizumab weekly or placebo for 48 weeks. Patients receiving tocilizumab had a 0.1% mean decline in forced vital capacity (FVC) over the study period, while those receiving placebo reported a mean decline of 6.3%... (Medscape)
To comment on this article,
create a free account.
Sign Up
to instantly read 30000+ free Articles & 1000+ Case Studies
Already registered?
.jpg)
great